Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomised, Multi-centric, Multi-national Clinical Trial to Evaluate the Efficacy, Tolerability, and Safety of a Fixed Dose Combination of Spironolactone, Pioglitazone & Metformin (SPIOMET) for Adolescent Girls and Young Adult Women (AYAs) With Polycystic Ovary Syndrome (PCOS)

NCT05394142 is registered in ClinicalTrials.gov with Fundació Sant Joan de Déu as lead sponsor.

NCT NCT05394142
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05394142 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomised, Multi-centric, Multi-national Clinical Trial to Evaluate the Efficacy, Tolerability, and Safety of a Fixed Dose Combination of Spironolactone, Pioglitazone & Metformin (SPIOMET) for Adolescent Girls and Young Adult Women (AYAs) With Polycystic Ovary Syndrome (PCOS)
Lead sponsor
Fundació Sant Joan de Déu
Phase
Phase 2
Overall status
Unknown status
Start date
May 24, 2022
Completion date
April 30, 2025
Enrollment
364 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

polycystic ovary syndrome (pcos)